Nearly one out of every seven households in the United States is affected by a neurological disease. Yet these devastating conditions, which cause the progressive loss of memory, mobility, cognition, or a combination of symptoms, have few treatments and none have cures. It is often difficult to diagnose many of these diseases even after the onset of symptoms. Genomic research holds incredible promise to help untangle diseases like Alzheimer’s, Huntington’s, and Parkinson’s, as well as rarer conditions such as ALS, frontotemporal dementia (FTD), and corticobasal syndrome (CBS).
Scientists at HudsonAlpha are studying the intricacies of the brain and nervous system and the diseases that affect them. With a clearer understanding of this incredibly complex organ and how cells are affected by genomic changes, we can impact neurodegenerative diseases in multiple ways. Because these conditions are often interrelated, a discovery in one disease can lead to knowledge that helps others. HudsonAlpha’s Memory and Mobility Program provides funding for important research that is advancing our knowledge of neurodegenerative diseases and unlocking new possibilities for better diagnostics and drug treatments.
The M&M Program is part of the Scientific Advancement fund within the HudsonAlpha Foundation. The HudsonAlpha Foundation, a 501(c)(3) nonprofit organization, is the supporting entity for the HudsonAlpha Institute for Biotechnology. Tax-deductible contributions to the foundation are for the sole purpose of advancing the mission of the HudsonAlpha Institute for Biotechnology.
Tax identification #27-2320591